Highlights
GlobalBio Inc.

Relying on over 20 years of experience in the field of antibody engineering and supported in part by The National Science Foundation, GlobalBio, Inc. was founded in 2014 to develop methods to engineer better and more developable therapeutic antibodies.

Based on these methods, GlobalBio has signed and executed numerous contracts to optimize and develop antibody-based therapeutics for use in Immuno-Oncology, Oncology and Infectious Diseases.


Founder & CEO

Dr. Juan C. Almagro is an expert in the fields of antibody engineering and development of biologic therapeutics, with 30+ years of experience in the Pharma/Biotech Industry and academic settings. In the Pharma/Biotech industry occupied positions of Sr. Director at Pfizer, and Scientific Director and Head of Antibody Design at Johnson & Johnson. In academia, was Visiting Scientist at Fred Hutchinson Cancer Research Center, Invited Professor at Simon Fraser University, Associate Professor at The National University of Mexico and Professor at National Polytechnic Institute of Mexico

RELEVANT PUBLICATIONS
INVITED REVIEWS
BOOK CHAPTERS
REVELANT PATENTS

  • RELEVANT PUBLICATIONS

  • BOOK CHAPTERS

  • REVELANT PATENTS

Awesome Image

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Neutralizing human anti-CD27 antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 05/19/2020. US Patent: 11,732,050. Issued: 08/22/2023.

Awesome Image

Manning PT, Puro R, Almagro JC. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,692,035. Issued: 07/04/2023.

Awesome Image

Puro R, Hiebsch RR, Capoccia BJ., Andrejeva G, Almagro JC, Pereira DS. Therapeutic SIRP-alpha. antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,202,828. Issued: 12/21/2021.

Awesome Image

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating osteoarthritis with human oncostatin M antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 12/10/2018. US Patent: 10,941,197. Issued: 03/09/2021.

Awesome Image

Manning PT, Puro R, Almagro JC, Karr RW. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. Priority Date: 02/08/2019. US Patent: 10,844,124. Issued: 11/24/2020.

Awesome Image

Gulla SV, Huard C, Buhlmann, JE, Almagro JC, Kodangattil SR, Coyle AJ. Interferon Beta Antibodies and Uses Thereof. Assignee: PFIZER, INC. Priority Date: 04/29/2016. US Patent: 10,829,553. Issued: 11/10/2020.

Awesome Image

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,689,453. Issued: 06/23/2020.

Awesome Image

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,301,392. Issued: 05/28/2019.

Awesome Image

Manning P, Puro R, Almagro JC, Karr RW. Therapeutic CD47 Antibodies. US Patent: 10,239,945. Assignee: Arch Oncology, Inc. Issued: 03/26/2019.

Awesome Image

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies. JANSSEN BIOTECH, INC. US Patent: 10,179,812. Issued: 01/15/2019.

  • Invited Reviews